Application of CTCF inhibitor in preparation of medicine for preventing and / or treating acute myocardial infarction
By using the CTCF inhibitor Difome to inhibit the secretion of inflammatory factors and abnormal proliferation of myocardial fibroblasts after myocardial infarction, the problem of fibrosis and inflammatory response after acute myocardial infarction is solved, cardiac function and hemodynamics are improved, and new treatments are provided means.
Patent Information
- Application Number
- CN202411465710.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-10-21
- Publication Date
- 2024-11-29
AI Technical Summary
The role of CTGF in the treatment of acute myocardial infarction in the prior art has not yet been clarified, and there is a lack of effective measures to prevent and treat ventricular remodeling after myocardial infarction, which makes it difficult to effectively control cardiac fibrosis and related complications after myocardial infarction.
Using 3-nitro-N-(4-phenoxyphenyl)benzamide (Difome) as a CTCF inhibitor, provides a new treatment by inhibiting the secretion of inflammatory factors after MI and abnormal proliferation of myocardial fibroblasts. Drugs for acute myocardial infarction, used to reduce cardiac fibrosis and inflammatory response.
Difome effectively inhibits myocardial fibrosis and inflammatory response after myocardial infarction, improves myocardial hemodynamics, reduces cardiac fibrosis and related complications, improves cardiac contraction/diastolic ability, and provides new effective treatment for acute myocardial infarction. means.
Smart Images

Figure CN119033746A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of medicine and relates to a therapeutic drug for acute myocardial infarction, and specifically relates to an application of a CTCF inhibitor in the preparation of a drug for preventing and / or treating acute myocardial infarction. Background Art
[0002] Myocardial infarction (MI) is a serious cardiovascular disease. Due to partial or complete blockage of the coronary artery, blood circulation is impaired, resulting in local necrosis of part of the myocardium due to persistent ischemia and hypoxia. The clinical manifestations of myocardial infarction include: pain and fever behind the sternum, leukocytosis, accelerated erythrocyte sedimentation rate, increased activity of creatine kinase isoenzyme CK-MB, troponin I (cTnI) or troponin T (cTnT), and progressive electrocardiogram changes. Arrhythmia, shock or heart failure may occur.
[0003] Myocardial infarction will trigger a series of pathological manifestations, and multiple cell signaling pathways will be activated. First, oxidative stress and tissue death occur, especially apoptotic and necrotic cardiomyocytes, which trigger an inflammatory response. Immune cells infiltrate the infarct area and release inflammatory factors. At the same time, myocardial fibroblasts transform into myofibroblasts, secrete extracellular matrix, and endothelial cells migrate and proliferate to form a vascular network to promote cardiac repair. Pathological myocardial hypertrophy under the action of inflammation, coupled with reactive fibrosis, will eventually lead to cardiac remodeling and heart failure. There are currently targeted targeted treatment strategies for different pathological manifestations, including anti-inflammation, anti-fibrosis, cardioprotection and cardiac regeneration, and angiogenesis.
[0004] Connective tissue growth factor (CTGF) is a cysteine-rich secretory growth factor belonging to the CCN family, also known as CCN2. As its name suggests, CTGF was originally found to promote the proliferation, migration, attachment and extracellular matrix formation of fibroblasts. The transcription of CTGF can be activated by TGF-β (transforming growth factor-beta), and it is an important downstream regulator of TGF-β's fibrogenic effects. On the basis of these findings, CTGF is considered to be a pro-fibrotic factor that plays an important role in the fibrosis process. At present, there is evidence that its physiological function is not limited to connective tissue growth. It has four different cytokine binding domains, including the IGFBP domain, the VWC domain, the TSP1 domain, and the CT domain. The four separate domains can function separately in vivo, which can not only increase the accumulation of extracellular matrix, induce cell fibrosis, promote collagen deposition and thus aggravate the process of fibrosis, but also inhibit angiogenesis and affect wound healing. Therefore, CTGF is related to fibrosis, wound healing, cartilage formation, angiogenesis, differentiation and metastasis, and tumor growth.
[0005] Myocardial infarction is myocardial necrosis caused by persistent ischemia and hypoxia of the coronary arteries, and is one of the main causes of death from cardiovascular diseases. Modern medical methods for treating myocardial infarction are becoming increasingly mature, but there are still problems such as restenosis after interventional treatment, reperfusion arrhythmia, no reflow phenomenon, and drug resistance. And heart failure is easily induced after myocardial infarction, which requires patients to pay attention to prognosis treatment after illness, and adherence to drug treatment can effectively improve complications. For this reason, the CTGF inhibitor screened out by the present invention can effectively reduce the degree of cardiac fibrosis after myocardial infarction, reduce cardiac scars and collagen deposition, and can play an anti-inflammatory role to a certain extent, and has a good therapeutic effect. The CTGF inhibitor disclosed in the present invention focuses on preventing and treating ventricular remodeling after myocardial infarction, so that the function of the heart is protected and maintained, the blood supply of the myocardium is improved, the dying myocardium is saved, the range of myocardial infarction is reduced, myocardial fibrosis and related complications after myocardial infarction are alleviated, and the role of preventing heart failure is played. Summary of the invention
[0006] The present invention aims to overcome the defects in the prior art that the role of CTGF in the treatment of acute myocardial infarction is not yet clear and there are few measures to prevent and treat ventricular remodeling after myocardial infarction. It provides a use of a CTCF inhibitor in the preparation of a drug for preventing and / or treating acute myocardial infarction, and discloses the mechanism of action of the CTCF inhibitor by inhibiting the secretion of inflammatory factors after myocardial infarction and then inhibiting the abnormal proliferation of myocardial fibroblasts, thereby providing a new treatment for myocardial fibrosis and related complications after acute myocardial infarction.
[0007] In order to achieve the purpose of the above invention, the present invention is implemented by the following technical solutions:
[0008] In a first aspect, the present invention discloses a use of a CTCF inhibitor in the preparation of a drug for preventing and / or treating acute myocardial infarction, wherein the CTCF inhibitor is 3-nitro-N-(4-phenoxyphenyl)benzamide (hereinafter referred to as Difome), which has the following chemical formula:
[0009] In a second aspect, the present invention further discloses the use of a CTCF inhibitor in the preparation of a drug for improving cardiac contraction / relaxation ability, wherein the CTCF inhibitor is 3-nitro-N-(4-phenoxyphenyl)benzamide.
[0010] In a third aspect, the present invention further discloses the use of a CTCF inhibitor in the preparation of a drug for inhibiting myocardial cell fibrosis, wherein the CTCF inhibitor is 3-nitro-N-(4-phenoxyphenyl)benzamide.
[0011] In a fourth aspect, the present invention further discloses the use of a CTCF inhibitor in the preparation of a drug for inhibiting abnormal proliferation of cardiac fibroblasts, wherein the CTCF inhibitor is 3-nitro-N-(4-phenoxyphenyl)benzamide.
[0012] In a fifth aspect, the present invention also discloses the use of a CTCF inhibitor in the preparation of a drug for inhibiting the secretion of inflammatory factors after myocardial infarction, wherein the CTCF inhibitor is 3-nitro-N-(4-phenoxyphenyl)benzamide.
[0013] Furthermore, the single dosage of the above-mentioned CTCF inhibitor 3-nitro-N-(4-phenoxyphenyl)benzamide for treating acute myocardial infarction in adults is 0.5 to 3 mg / kg / d.
[0014] In a sixth aspect, the present invention further discloses a drug for treating acute myocardial infarction, characterized in that the drug comprises the CTCF inhibitor 3-nitro-N-(4-phenoxyphenyl)benzamide described in the first aspect of the present invention.
[0015] Furthermore, the dosage form of the above-mentioned drug is one of injection, capsule, tablet, granule, suspension, emulsion, spray, powder, liposome, oral solution and pill.
[0016] Furthermore, the administration method of the above-mentioned drug is one or more of intramuscular injection, subcutaneous injection, intravenous injection, oral administration, sublingual administration, intralesional or intracerebral delivery, and spray administration.
[0017] In a seventh aspect, the present invention further discloses a method for preparing a drug for treating acute myocardial infarction, comprising: mixing the CTCF inhibitor described in the first aspect of the present invention with a pharmaceutically acceptable carrier or excipient to form a mixed drug preparation.
[0018] Therefore, the present invention has the following beneficial effects: (1) The present invention discloses a CTGF inhibitor Difome, which inhibits the secretion of inflammatory factors after myocardial infarction and then inhibits the abnormal proliferation of myocardial fibroblasts, thereby achieving the mechanism of action of preventing and / or treating acute myocardial infarction. (2) The present invention constructs a rat myocardial infarction model and discloses the efficacy of the CTGF inhibitor Difome in improving the hemodynamics of rats with myocardial infarction, improving myocardial inflammation after myocardial infarction, and improving myocardial fibrosis factors after myocardial infarction. (3) The present invention provides new evidence that CTCF inhibitors are effective drugs for treating myocardial infarction, and provides a new treatment for myocardial fibrosis and related complications after myocardial infarction. BRIEF DESCRIPTION OF THE DRAWINGS
[0019] Figure 1 These are fluorescence microscopy images of Edu staining of cells in each group in the cell proliferation inhibition assay.
[0020] Figure 2 This is a comparison chart of the proliferation rate of rat fibroblasts in each group in the cell proliferation inhibition test.
[0021] Figure 3 This is a scatter plot of the survival status of myocardial fibroblasts in each group of rats during cell apoptosis detection.
[0022] Figure 4 This is a comparison chart of the apoptosis rates of myocardial fibroblasts in each group of rats in cell apoptosis detection.
[0023] Figure 5 These are the scratch images of cardiac fibroblasts of rats in each group in the cell scratch experiment.
[0024] Figure 6 This is a comparison chart of the migration rates of cardiac fibroblasts in each group of rats in the cell scratch experiment.
[0025] Figure 7 Schematic diagram of the effect of CTGF inhibitor Difome on hemodynamics in rats with myocardial infarction.
[0026] Figure 8 This is a comparison chart of hemodynamic indicators in each group in the hemodynamic experiment.
[0027] Fig. 9 This is a comparison chart of the levels of serum inflammatory factors in each group of rat serum.
[0028] Fig.10These are light microscopic images of each group in the Masson-stained pathological section experiment of rat heart tissue.
[0029] Fig.11 This is a comparison chart of the myocardial fibrosis area ratio in the Masson staining pathological section experiment of rat heart tissue. DETAILED DESCRIPTION
[0030] The present invention is further described below in conjunction with specific embodiments. Those of ordinary skill in the art will be able to implement the present invention based on these descriptions. In addition, the embodiments of the present invention involved in the following description are generally only embodiments of a part of the present invention, rather than all embodiments. Therefore, based on the embodiments in the present invention, all other embodiments obtained by those of ordinary skill in the art without making creative work should fall within the scope of protection of the present invention.
[0031] Rat myocardial fibroblasts were cultured in vitro, and blank control group (Control), model group (Model), Difome high-dose group (Difome-High), Difome low-dose group (Difome-Low), and positive drug group (CLP) were set up. The blank control group was cultured normally, and the model group and drug group were incubated with PDGF-BB (platelet-derived factor) for 24 hours to establish a massive proliferation model of myocardial fibroblasts.
[0032] To verify the effect of CTGF inhibitor Difome on inhibiting abnormal proliferation of cardiac fibroblasts, the above groups were tested for cell proliferation inhibition using Edu / MTT assay 24 hours after administration: (1) After the cell suspension is prepared, mix gently and add 90ul of cell suspension to each well to make the density of the cells to be tested 8000 per well (the edge wells are filled with sterile PBS), and culture in a 5% CO2, 37°C incubator for 24 hours; (2) When the cells were completely attached, they were randomly divided into 5 groups. PDGF-BB was prepared at the required concentration and added to the wells of the model group and the drug-treated group. The cells were cultured in a 5% CO2, 37°C incubator for 24 h. (3) Prepare the drugs according to the required concentration gradient. The drug concentration of the Difome high-dose group is 2 mg / kg, and the drug concentration of the Difome low-dose group is 1 mg / kg. Add 10 uL to each well and culture in a 5% CO2, 37°C incubator for 24 h. (4) Aspirate the supernatant and add 50uL of Edu working solution and incubate for 1-2h. Remove the working solution, add fixative solution for 15min, wash three times with washing solution, add permeabilization solution and incubate for 10min, wash again and add 50uL of Click reaction solution, incubate at room temperature in the dark for 30min, remove the reaction solution and wash three times, finally seal the slides with anti-fluorescence quenching sealing solution containing DAPI, observe the Edu staining of each group of cells under a fluorescence microscope, and calculate the relative cell proliferation rate.
[0033] The experimental results are as follows Figure 1 , Figure 2 As shown, compared with the normal group, the cell proliferation rate in the model group was significantly increased; after intervention with the Difome high-dose group, Difome low-dose group, and positive drug group, the cell proliferation rate was significantly lower than that in the model group, indicating that Difome has a strong anti-proliferative property on PDGF-BB-induced myocardial fibroblasts.
[0034] To verify the effect of CTGF inhibitor Difome in inducing apoptosis of cardiac fibroblasts, apoptosis detection was performed on the above groups: (1) The cells in the logarithmic phase were digested with 0.25% trypsin and the cell density was adjusted to make up the remaining culture volume. When the cells were completely attached to the wall, they were randomly divided into 5 groups and cultured for 48 h after corresponding treatment. (2) The culture supernatant in each well was discarded, and the cells were digested with 0.25% trypsin. The cells were collected into a new centrifuge tube and washed 2 to 3 times with PBS buffer (1000 uL, 3000 rpm for 1 min); (3) Add an appropriate amount of incubation buffer to the above centrifuge tube to resuspend the cells at the bottom of the tube, then add 5uL AnnexinV-FICT, mix thoroughly and place in a dark room to react for 10 minutes; (4) Add 1uLPI (100ug / ul) staining solution to the above centrifuge tube, mix thoroughly and react in a dark environment for 5 minutes. Use a pipette to draw 400uL of binding buffer into the centrifuge tube after the reaction is complete, and use flow cytometry for analysis and detection. Repeat this experiment 3 times; the number of cells detected in each sample is 10,000.
[0035] The results are as follows Figure 3 As shown, the test results are expressed in a scatter plot, where the lower left quadrant represents the proportion of live cells (FICT- / PI); the upper right quadrant represents the proportion of necrotic cells (FICT+ / PI+); and the lower right quadrant represents the proportion of apoptotic cells (FICT+ / PI). Figure 4As shown, compared with the normal group, the cell apoptosis rate in the model group was significantly decreased (P<0.01). After intervention in the Difome high-dose group and the Difome low-dose group, the cell apoptosis rate was effectively increased.
[0036] To verify the inhibitory effect of CTGF inhibitor Difome on fibroblast migration, cell scratch assay was performed on the above groups: (1) Use a black marker to draw two parallel straight lines on the outside bottom of the six-well plate to determine the scratch position for easy observation under a microscope. (2) Rat cardiac fibroblasts were seeded into six-well plates and incubated in an incubator for 24 h until the cells were basically fused. The culture medium in each well was aspirated, and a 1 mL pipette tip was used to draw a line in the air from top to bottom. The plates were washed three times with PBS to remove the scraped cells, and then the drugs were administered according to the groups and incubated for another 24 h. (3) Observe the cells at the scratch site under a microscope and take photos at 0 h and 24 h.
[0037] The results are as follows Figure 5 As shown, the scratch images showed that the CTGF inhibitor Difome could inhibit the migration of rat cardiac fibroblasts; Figure 6 As shown, compared with the model group, the high-dose and low-dose Difome groups could significantly inhibit the migration ability of rat myocardial fibroblasts.
[0038] In order to further verify the effect of CTGF inhibitor Difome in animals, a rat model of myocardial ischemia injury was established: Rats were weighed, 20% urethane was injected intraperitoneally, the dosage was 0.6ml / 100g, and after the rats were anesthetized, they were fixed on the mouse board in supine position, endotracheal intubation was performed, and a small animal ventilator was connected (the tidal volume was adjusted to 5ml, and the respiratory rate was 60-70 times / min). The electrocardiogram was connected, the left lower limb was the positive electrode, the right upper limb was the negative electrode, and the left lower limb was grounded. The electrocardiogram was observed, and mice with abnormal electrocardiograms were not used for the experiment. The left chest of the rat was shaved, the skin was disinfected with 75% alcohol, the skin was cut from the left side of the sternum, the incision was about 2cm, and the subcutaneous and muscle tissues were bluntly separated using hemostatic forceps to completely expose the third and fourth ribs. The third and fourth intercostal muscles were separated with hemostatic forceps to expose the heart to the visual field, the pericardium was torn, and the left anterior descending branch of the coronary artery was found between the arterial cone and the left atrial appendage. A 7-0 fine silk thread was selected to pass through the myocardium under the left anterior descending branch of the coronary artery. The depth of entering the myocardium should be about 3mm, and too deep may cause penetration of the left ventricle. The myocardium was tied with silk thread, the ischemic part of the myocardium turned white, and the ST segment of the electrocardiogram was arched and elevated, indicating that the myocardial infarction model was successful. After confirming that the model was successful, the ribs were sutured immediately. After the ribs were sutured, the muscles and skin were sutured layer by layer. The surgical area was disinfected with iodine tincture, and 80,000 units of penicillin were injected intramuscularly for three consecutive days. The ventilator was removed and the endotracheal tube was retained to observe whether the rats recovered spontaneous breathing. If they had recovered, the endotracheal tube was removed, foreign objects in the mouth were cleaned, and they were placed on a warming blanket until they were fully awake. The experimental animals were randomly divided into 5 groups, namely: blank control group, model group, Difome high (2mg / kg), low-dose group (1mg / kg), and positive drug clopidogrel group (7.5mg / kg). The administration time was 7 days, once a day.
[0039] In order to verify that the CTGF inhibitor Difome improves the cardiac contraction / relaxation ability of rats with myocardial infarction, hemodynamic experiments were conducted: (1) The anesthetized rats were fixed on a mouse board in supine position. The neck skin was cut open, the distal end of the right common carotid artery was carefully separated and ligated with a 4-0 suture, and the proximal end was clamped with a vascular clamp. (2) Use ophthalmic scissors to make a V-shaped opening in the right common carotid artery, use ophthalmic forceps to pry open the blood vessel, insert a PE-10 catheter, loosen the vascular clamp, and test the aortic pressure. After the animal's condition stabilizes, continue to insert the PE-10 catheter into the left ventricle to test the intraventricular pressure. (3) After the measurement is completed, carefully remove the catheter and place it in normal saline, and tie the suture on the right common carotid artery of the rat to avoid bleeding. During data analysis, hemodynamic indicators such as LVSP (left ventricular systolic pressure), Max dP / dt (maximum rate of change in the rising phase of left ventricular pressure), Min dP / dt (maximum rate of decrease in the falling phase of left ventricular pressure), and LVEDP (left ventricular end-diastolic pressure) were calculated.
[0040] The experimental results are as follows Figure 7 , Figure 8As shown in the figure, the effect of Difome on the hemodynamics of rats with myocardial infarction after 7 days of administration is shown in the figure. The use of Difome high and low groups can reduce the preload by reducing the resistance of dilated peripheral blood vessels and improving the ability of cardiac diastole, thereby improving the systolic / diastolic function of the heart in rats with myocardial ischemia; after coronary artery ligation, the Max dP / dt and Min dP / dt of each group were significantly lower than those before ligation; compared with the model group, the Difome administration group reduced the decrease in Max dP / dt. This shows that Difome can effectively improve the systolic / diastolic ability of the heart in rats with myocardial ischemia by resisting the decrease in Max dP / dt and Min dP / dt, so as to maintain the systolic / diastolic function of the heart.
[0041] In order to verify the inhibitory effect of CTGF inhibitor Difome on inflammatory factors and fibrosis factors in rats with myocardial infarction, ELISA kits were used to measure the levels of TNF-α (tumor necrosis factor-α), IL-6 (interleukin-6), TGF-β (transforming growth factor-β) and FN (fibronectin) in the serum of rats in each group: (1) Blood was collected from the abdominal aorta of the rats 7 days after administration, and the blood was allowed to stand at 4°C for 1 hour, and then centrifuged in a low-temperature centrifuge for 10 minutes at 3000 rpm and 4°C. The supernatant was then removed and stored at -80°C. (2) According to the experimental scheme provided in the ELISA kit, the contents of TNF-α, IL-6, TGF-β, and FN were quantitatively detected.
[0042] TNF-α, IL-6, TGF-β and FN are common serum inflammatory factors that increase significantly after myocardial infarction, and their levels are also related to myocardial fibrosis. Fig. 9 The results showed that compared with the normal group, the serum TNF-α, IL-6, TGF-β and FN levels of the model group rats were significantly increased, and the systemic inflammatory response of the rats after myocardial infarction was severe. After Difome treatment, the serum TNF-α, IL-6, TGF-β and FN levels of the Difome-treated rats decreased, indicating that Difome can inhibit the inflammatory response after myocardial infarction and inhibit the process of myocardial fibrosis.
[0043] In order to verify the improvement effect of CTGF inhibitor Difome on myocardial fibrosis in rats with myocardial infarction, Masson staining pathological section experiments of rat heart tissue were performed: After killing the rat, the heart was quickly removed, rinsed with ice saline, and immersed in 4% paraformaldehyde. Cotton was stuffed into the bottle containing the specimen so that the lung tissue was completely immersed in paraformaldehyde. After fixation at room temperature for 24 hours, the heart was paraffin-embedded and sectioned for Masson staining.
[0044] The experimental results are as follows Fig.10 The figure shows the light microscopic image of Masson-stained pathological sections of rat heart tissue, and the ratio of myocardial fibrosis area is shown in Fig.11 As shown. The results of Masson staining showed that the red myocardial fibers of the normal group rats were neatly arranged, and the blue collagen fibers were rare; after myocardial infarction, myocardial cells were necrotic, the myocardial tissue structure was disordered, and a large area of blue collagen fibers could be seen in the infarcted area. The myocardial tissue structure of the rats in the Difome administration group was improved to a certain extent, the red myocardial cells and blue collagen in the infarcted area were distributed alternately, and the collagen fibers were significantly reduced, indicating that the CTGF inhibitor Difome can reduce the degree of myocardial fibrosis after myocardial infarction after 7 days.
Claims
1. Use of a CTCF inhibitor in the preparation of a drug for preventing and / or treating acute myocardial infarction, characterized in that: The CTCF inhibitor is 3-nitro-N-(4-phenoxyphenyl)benzamide, and the CTCF inhibitor has the following chemical formula:
2. A use of the CTCF inhibitor as claimed in claim 1 in the preparation of a drug for improving cardiac contraction / relaxation ability.
3. Use of the CTCF inhibitor as claimed in claim 1 in the preparation of a drug for inhibiting myocardial cell fibrosis.
4. Use of the CTCF inhibitor as claimed in claim 1 in the preparation of a drug for inhibiting abnormal proliferation of cardiac fibroblasts.
5. Use of the CTCF inhibitor as claimed in claim 1 in the preparation of a drug for inhibiting the secretion of inflammatory factors after myocardial infarction.
6. The use according to any one of claims 1 to 5, characterized in that: The single dosage of the CTCF inhibitor for treating acute myocardial infarction in adults is 0.5 to 3 mg / kg / d.
7. A drug for treating acute myocardial infarction, characterized in that: The drug comprises the CTCF inhibitor 3-nitro-N-(4-phenoxyphenyl)benzamide as claimed in claim 1.
8. A drug for treating acute myocardial infarction according to claim 7, characterized in that: The dosage form of the drug is one of injection, capsule, tablet, granule, suspension, emulsion, spray, powder, liposome, oral solution and pill.
9. A drug for treating acute myocardial infarction according to claim 7, characterized in that: The administration method of the drug is one or more of intramuscular injection, subcutaneous injection, intravenous injection, oral administration, sublingual administration, intralesional or intracerebral delivery, and spray administration.
10. A method for preparing a drug for treating acute myocardial infarction, characterized in that: The CTCF inhibitor according to claim 1 is mixed with a pharmaceutically acceptable carrier or excipient to form a mixed drug preparation.
